Search PubMedSearch

Biomedical subjects

Xiaobo Yu

Publications and source records attributed to Xiaobo Yu.

2 recordsLinked to original sources

Unlocking the Circulating Proteome: Toward Clinical Translation.

Blood-based proteomics is approaching a translational inflection point. Driven by advances in measurement technologies, rapid expansion of analytical capabilities, and growing adoption across research and medical communities, there is increasing demand for clinically actionable biomarkers. As the field transitions away from purely large-scale discovery-oriented studies toward more informed, targeted, application-driven analyses, the generation of proteomic data is no longer the bottleneck. Instead, the central challenge is to translate these measurements into robust, reproducible, and clinically meaningful insights. In this Review, we assess recent technological and methodological developments, evaluate persistent preanalytical and interpretative limitations, and outline the key steps required for clinical translation. We focus on three deeply interconnected dimensions: the capabilities and constraints of current measurement platforms, the role of computational and machine learning approaches in extracting biological and clinical signals, and the emergence of large-scale population studies that create new opportunities for validation and generalization. Finally, we discuss a forward-looking vision in which proteomics plays a central role in dynamic, multilayered omics frameworks, where integration with genomics, temporal profiling, and imaging can deepen our understanding of health, disease, and therapeutic response.

Humans

Population proteomics for equitable precision medicine.

Population proteomics is emerging as a new framework for equitable precision medicine. By studying protein variation across populations, this field bridges population genomics and conventional proteomics to capture the functional molecular states through which genetic ancestry, environmental exposures and other contextual factors shape human health. Here, we discuss how recent advances are moving population proteomics beyond biomarker discovery toward equitable clinical translation through cross-population validation, mechanistic multiomics and global research infrastructures. Its ultimate promise is not to classify populations as fixed biological categories, but to make human diversity measurable, interpretable and clinically actionable for equitable precision medicine.

Journal Article